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ABSTR ACT: The recently approved angiotensin II receptor blocker, azilsartan medoxomil (AZL), was determined spectrophotometrically and spectroflu-
orimetrically in its combination with chlorthalidone (CLT) in their combined dosage form. The UV-spectrophotometric technique depends on simultane-
ous measurement of the first derivative spectra for AZL and CLT at 286 and 257 nm, respectively, in methanol. The spectrofluorimetric technique depends 
on measurement of the fourth derivative of the synchronous spectra intensities of AZL in presence of CLT at 298 nm in methanol. The effects of different 
solvents on spectrophotometric and spectrofluorimetric responses were studied. For, the spectrofluorimetric study, the effect of pH and micelle-assisted 
fluorescence enhancement were also studied. Linearity, accuracy, and precision were found to be satisfactory over the concentration ranges of 8–50 µg mL-1 
and 2–20 µg mL-1 for AZL and CLT, respectively, in the spectrophotometric method as well as 0.01–0.08 µg mL-1 for AZL in the spectrofluorimetric 
method. The methods were successfully applied for the determination of the studied drugs in their co-formulated tablets. The developed methods are inex-
pensive and simple for the quality control and routine analysis of the cited drugs in bulk and in pharmaceuticals.
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1. Introduction
Azilsartan medoxomil (AZL) (5-methyl-2-oxo-1,3-dioxol-4yl) 
methyl 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-
3-yl) biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxyl-
ate—Figure 1a—is practically insoluble in water, freely soluble 
in methanol and dimethylsulfoxide, soluble in acetic acid, 
slightly soluble in acetone and acetonitrile, and sparingly sol-
uble in tetrahydrofuran and 1-octanol.1 Azilsartan, the active 
metabolite of AZL, is a novel non-peptide angiotensin II type 
1 (AT1) receptor blocker (ARB) that was recently approved for 
treatment of hypertension.2 It has a superior ability to con-
trol systolic blood pressure (BP) relative to other widely used 
ARBs. Greater antihypertensive effects of AZL might be in 
part because of its unusually potent and persistent ability to 
inhibit binding of angiotensin II to AT1 receptors.3 Preclinical 
studies have indicated that AZL may also beneficially affect 
cellular mechanisms of cardio-metabolic disease and insulin 
sensitizing activity.4 There is only one reported method1 for 
determination of AZL alone, and it was applied to its analysis in 
plasma. Chlorthalidone (CLT) (2-chloro-5-(1-hydroxy-3-oxoiso-
indolin-1-yl) benzenesulfonamide)—Figure 1b—is an orally 
taken thiazide-like diuretic for controlling hypertension and 
edema, including that associated with heart failure.5 CLT has 
been determined in different matrices either alone or in com-
bination with other medications using LC,6,7 LC-MS/MS,8 
HPTLC,9,10 chemiluminometry,11 spectrophotometry,12 and 
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Figure 1. Chemical structures for (a) AZL and (b) clt.
CE13 techniques. Binary combination therapies of AZL and 
CLT proved to induce significant reductions in systolic and 
diastolic BP in patients with mild to severe hypertension.14 
Accordingly, it is desirable to develop validated simple ana-
lytical methods for assay of AZL in its combination with 
CLT either in their laboratory prepared mixtures or in their 
combined pharmaceutical preparations. Regarding simulta-
neous determination of CLT and AZL, there is only one LC 
reported method15 that was done on a symmetry C18 column 
with a mobile phase consisting of methanol:water:acetonitr
ile:0.1% ortho phosphoric acid (30:35:15:5, v/v/v/v) at detec-
tion l of 251 nm. To the best of our knowledge, there is no 
reported spectrophotometric or spectrofluorimetric methods 
for determination of AZL either alone or in its combination 
with CLT. Hence, the aim of these studies was to develop and 
validate simple, rapid, and inexpensive analytical methods 
using the spectrophotometric and spectrofluorimetric tech-
niques for determination of AZL in its combination with CLT 
to be applied to their determination in pharmaceuticals. These 
newly developed and validated methods can be used for rou-
tine analysis and quality control of the cited medications either 
separately or in combination without pre-separation.
2. Experimental
2.1. Materials and reagents. All chemicals used were of 
analytical reagent grade, and solvents were of HPLC grade. 
CLT (certified to contain 98%) was supplied by Ark Pharm. 
Inc., IL 60048 USA. AZL (certified to contain 98%) was 
supplied by D-L Chiral Chemicals, LLC, NJ 08540, USA. 
Edarbyclor® 40/25  mg tablets, batch NDC 64764-0994-30 
(Takeda Pharmaceutical Company Limited, Tokyo, Japan), 
each labeled to contain 42.68 mg of azilsartan kamedoxomil 
(equivalent to 40 mg AZL) and 25 mg CLT were purchased 
from commercial sources in the local market. Methanol, 
sodium dodecyl sulphate (SDS), cetyltrimethylammonium 
bromide (CTAB), and hydroxymethylcellulose (HMC) were 
obtained from Sigma-Aldrich, MO, USA, and b-cyclodex-
trin (b-CD) from TCI, Tokyo Kasei, Japan. O-phosphoric 
acid 85% and hydrochloric acid (Fisher Scientific, NJ, USA) 
were used. Sodium hydroxide and sodium dihydrogen phos-
phate were purchased from J.T. Baker, NJ, USA. Phosphate 
buffer  solutions (PBSs) (0.02 M) were freshly prepared. SDS, 
CTAB, b-CD, and HMC were prepared as 1% w/v aqueous 
solutions. Also, 0.1 N NaOH and 0.1 N HCl were prepared.
2.2. Instrument. A lambda 20 UV/Vis spectrometer 
(Perkin Elmer, MA, USA) was used for the spectrophotomet-
ric measurements, whereas a LS 55 fluorescence spectrometer, 
120 V (Perkin Elmer, MA, USA), was used for the spectro-
fluorimetric measurements. Spectrophotometric measure-
ments and data handling were performed using UV WinLab 
1.22 software, whereas fluorescence spectra measurements and 
data handling were performed using FL WinLab™ software. 
Quartz cells (1 cm) were used. A VWR symphony (SB20) pH 
meter (Thermo Orion, Beverly, MA, USA) was used for pH 
measurements. Deionized water was prepared using a Barn-
stead NANO pure diamond analytical ultrapure water system 
(Thermo Fischer Scientific, Waltham, MA, USA).
2.3. Standard stock solutions preparation. A total of 
10 mg of AZL and CLT were accurately weighed and trans-
ferred separately into 10 mL of volumetric flasks. Then, they 
were dissolved and made up to volume with methanol to 
give concentrations of 1000 µg mL-1 for each. Further dilu-
tions were made separately using the same solvent to prepare 
1 µg mL-1 solutions for each.
2.4. Procedures.
2.4.1. Linearity and construction of calibration graphs for 
the spectrophotometric technique. Aliquots of AZL and CLT 
standard stock solutions (1000  µg  mL-1) were separately 
transferred into two series of 10  mL Fisherbrand dispos-
able tubes to give final concentrations of 8–50 µg mL-1 and 
2–20 µg  mL-1 for AZL and CLT, respectively, then com-
pleted to 5 mL with methanol, and the contents were mixed 
well. The absorbance spectra were recorded against a metha-
nol blank and then the first derivative spectra were obtained 
(number of points = 18). The amplitudes at 286 and 257 nm 
for AZL and CLT, respectively, were measured and then 
plotted versus the corresponding final drug concentration of 
AZL and CLT (µg mL-1) to obtain the calibration graphs 
and regression equations.
2.4.2. Linearity and construction of calibration graphs for the 
spectrofluorimetric technique. Aliquots of AZL standard stock 
solution (1 µg mL-1) were transferred into a series of 10 mL 
Fisherbrand disposable tubes to give final concentrations in the 
range of 0.01–0.08 µg mL-1. Then, completed to 5 mL with 
methanol and the contents were mixed well. Relative fluores-
cence intensity (RFI) of the synchronous spectrofluorimetric 
spectra was recorded against a solvent blank using Dl = 110 nm 
(slit width for excitation and emission = 10 nm), and then the 
fourth derivatives were obtained (number of points = 90). The 
amplitudes of the fourth derivative of the synchronous spectra 
at 298 nm were measured and plotted versus the correspond-
ing final drug concentration of AZL (µg mL-1) to obtain the 
calibration graphs and regression equations.
2.4.3. Preparation of AZL and CLT laboratory prepared 
mixtures. For the spectrophotometric method, aliquots of 
AZL and CLT standard stock solutions (1,000  µg  mL-1) 
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Figure 2. Effect of different diluting solvents on the zero-order 
UV-absorbance spectra of (a) 20 µg ml-1 of AZL at 260 nm and  
(b) 8 µg ml-1 of CLT at 232 nm.
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Figure 3. Zero-order UV-absorbance spectra of (a) 8, 12, 20, 30, and 
50 µg ml-1 AZL and (b) 2, 4, 8, 12, 20 µg ml-1 CLT against (c) methanol blank.
were accurately transferred into a series of 10 mL Fisherbrand 
disposable tubes to give final concentrations of 9.6, 16.0, and 
24.0 µg mL-1 for AZL and 6.0, 10.0, and 15.0 µg mL-1 for 
CLT. The procedure described under section “2.4.1” was then 
applied. For the spectrofluorimetric method, aliquots of AZL 
and CLT standard stock solutions (1  µg  mL-1) were accu-
rately transferred into a series of 10 mL Fisherbrand dispos-
able tubes to give final concentrations of 0.0384, 0.0576, and 
0.0768 µg mL-1 for AZL and 0.0240, 0.0360, 0.0480 µg mL-1 
for CLT. The procedure described under section “2.4.2” was 
then applied. For both methods, the recovery percentage was 
calculated using the corresponding regression equation.
2.4.4. Sample preparation. 10 tablets of Edarbcyclor® were 
weighed and finely powdered after removal of the coat using 
a tissue moistened with methanol. A portion of the powder 
equivalent to AZL (40 mg) and CLT (25 mg) was introduced 
into a 25 mL volumetric flask to which 20 mL methanol were 
added and sonicated for 30 min. The solution was made up to 
volume using the same solvent and filtered through a Whatman 
filter paper, and then filtered again using a 0.2 µm Whatman 
inorganic membrane filter. For spectrophotometric analyses, 
different aliquots from the prepared sample solutions were 
scanned and manipulated using the same procedure described 
under section “2.4.1.” For the spectrofluorimetric analyses, 
further dilutions were prepared and different aliquots from 
the prepared sample solutions were scanned and manipulated 
using the same procedure described under section “2.4.2.” The 
percentage of recoveries were calculated by referring to the cor-
responding regression equations.
2.5. Validation. The suggested analytical method was 
validated according to ICH guidelines16 with respect to cer-
tain parameters such as linearity, limit of detection (LOD) 
and limit of quantitation (LOQ ), accuracy, precision, speci-
ficity, and stability.
3. Results and Discussion
The goal of the present investigations was to do some spec-
trophotometric and spectrophotometric studies on AZL and 
CLT in order to develop validated, rapid, sensitive, simple, 
inexpensive, and selective spectrophotometric and spectro-
fluorimetric analytical methods for quantification of AZL in 
its combination with CLT. These studies focused on factors 
that enhance the absorbance or the intensities for the emission 
bands of each analyte.
3.1. Optimization of the experimental conditions for 
the spectrophotometric technique. For the spectrophoto-
metric technique, the effect of different diluting solvents such 
as methanol, 0.1  N HCl, and 0.1  N NaOH on absorbance 
was studied. 0.1 N NaOH showed a slightly higher response 
for both drugs (Fig. 2). This solvent can be used for ordinary 
UV measurements of AZL or CLT separately at 260 and 
232 nm, respectively. Methanol was used as a convenient dilut-
ing solvent with satisfactory linearities in the range of 8–50 
and 2–20 µg  mL-1 for AZL and CLT at 266 and 242  nm, 
 respectively (Fig. 3). The spectra of AZL and CLT in all of the 
studied solvents showed severe overlap (Fig. 3). Obtaining the 
first derivative for the absorbance spectra of the analyzed drugs 
was able to resolve such overlapping between AZL and CLT, 
only in methanol, to be utilized for their simultaneous quanti-
tative determination at 286 and 257 nm, respectively (Fig. 4).
3.2. Optimization of the experimental conditions for 
the spectrofluorimetric technique.
3.2.1. Effect of diluting solvent. AZL is freely soluble in 
methanol, so it was added to the solvent media in at least 10% 
of the final volume and then either methanol, 0.1  N HCl, 
0.1 N NaOH, or PBS was added to complete the volume. The 
influence of these different diluting solvents on the RFI of 
AZL and CLT was studied, and methanol was chosen as it 
showed the highest RFI (Fig. 5).
3.2.2. Effect of pH. The effect of pH on RFI of AZL and 
CLT was investigated and pH 7.5 was found to give slightly 
higher RFI for AZL as its pKa value is 6.1, and it will have 
higher ionization percentage at this pH (Fig. 6). For CLT 
(pKa = 9.4), it is ionized at all of the studied pHs, so the effect 
of the studied pH values was not significant (Fig. 6).
Ebeid et al
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Figure 4. First derivative for the spectra of (a) 8, 12, 20, 30, and 
50 µg ml-1 of AZL and (b) 2, 4, 8, 12, 20 µg ml-1 of CLT against  
(c) methanol blank.
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Figure 5. Effect of different diluting solvents on the relative conventional 
fluorescence intensities for 0.02 µg ml-1 of AZL and CLT at 381 nm upon 
excitation at 260 nm using the described parameters.
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Figure 6. Effect of pH of PBS on the relative conventional fluorescence 
intensities for 0.02 µg ml-1 of AZL and CLT at 381 nm upon excitation at 
260 nm using the described parameters.
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Figure 7. Effect of different surfactants (1 mL of 1% w/v solution for each) 
on the relative conventional fluorescence intensities for 0.02 µg ml-1 of 
AZL and CLT at 381 nm upon excitation at 260 nm using the described 
parameters.
3.2.3. Effect of different organized media. The fluorescence 
properties of AZL and CLT in various micellar media were 
studied using anionic surfactant (SDS), cationic  surfactant 
(CTAB), as well as different macromolecules such as (b-CD) 
and (HMC). Micelles or reversed micelles are able to stabilize 
the exited singlet state and delay the decay process, and thus 
may enhance the intensity of the emission bands.17 PBS of pH 
7.5 was used through this study to allow proper ionization of 
both  analytes. None of the examined surfactants showed sig-
nificant enhancement in RFI of AZL and CLT (Fig. 7).
3.2.4. Techniques and parameters settings. Satisfactory lin-
earity was obtained for AZL and CLT in methanol at 381 and 
330 nm, upon excitation at 260 nm, respectively, at slit width 
of excitation and emission of 10 nm (Fig. 8, Table 1). How-
ever, the spectra of AZL and CLT in all of the studied sol-
vents showed severe overlap, so they cannot be used for their 
simultaneous determination (Fig. 8). Also, synchronous fluo-
rescence was not able to resolve such overlap at l = 10–300 nm 
(slit width for excitation and emission =  5–10  nm) (Fig. 9). 
Obtaining the fourth derivative for the synchronous fluo-
rescence spectra (l =  110  nm, slit width for excitation and 
emission = 10 nm) of the analyzed drugs was able to resolve 
such overlap between AZL and CLT, only in methanol, to be 
 utilized for quantitative determination of AZL in presence of 
CLT at 298 nm in their medicinally recommended ratio of 
1.6:1, respectively (Fig. 10).
3.3. Validation of the methods.
3.3.1. Linearity and range. Linear relationship between 
the responses of AZL or CLT and their corresponding con-
centrations was obtained. The regression equation y = bC ± a 
for each drug was also computed. In these studies, at least five 
 concentrations for AZL or CLT were used. The linearity of the 
calibration curves was validated by the high value of correla-
tion coefficients (r) of the regression equation, small values of 
the standard deviation of residuals (Sy/x), and small value of the 
percentage relative error (Table 1). The analytical data of the 
calibration curves including standard deviations for the slope 
and intercept (Sb, Sa) are summarized in Table 1. These data 
indicate the linearity of the calibration graphs.
3.3.2. Limit of detection and limit of quantification. LOQ 
and LOD were calculated according to ICH recommenda-
tions.17 LOD was considered as the minimum concentration 
with a signal to noise ratio of at least 3 (S/N ~3), whereas LOQ 
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Table 1. Performance data and results of the proposed spectroscopic methods.
ITEM SPECTROPHOTOMETRIC TECHNIQUE SPECTROFLUORIMETRIC TECHNIQUE
AZL
(D1)
CLT
(D1)
AZL
(D4)
AZL
(381 nm)
CLT
(330 nm)
Limit of detection, LOD (µg ml-1) 0.977 0.296 0.001 0.001 0.002
Limit of quantitation, LOQ (µg ml-1) 2.960 0.897 0.003 0.004 0.005
Intercept (a) 0.0064 -0.0154 0.7876 41.996 3.5339
Slope (b) 0.0075 0.0224 789.1 6289.8 3922.4
Correlation coefficient (r) 0.9998 0.9999 0.9998 0.9991 0.9996
S.D of residuals (Sy/x) 0.003 0.003 0.478 4.396 2.576
S.D of intercept (Sa) 0.002 0.002 0.267 2.469 2.043
S.D of slope (Sb) 0.001 0.001 8.048 74.453 61.598
Percentage relative error 0.75 0.55 0.76 0.94 1.23
Linearity range (µg/ml) 8.00-50.00 2.00-20.00 0.01-0.08 0.01-0.08 0.01-0.06
Mean recovery ± %R.S.D 99.55 ± 1.69 100.62 ± 1.24 99.94 ± 0.80 99.54 ± 2.09 100.61 ± 2.75
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Figure 8. Conventional emission spectra for 0.06 µg ml-1 of (a) AZL and (b) CLT upon excitation at 260 nm against (c) methanol blank using the described 
parameters.
was taken as a minimum concentration with a signal to noise 
ratio of at least 10 (S/N ~10). Results are given in Table 1.
3.3.3. Accuracy and precision. The satisfactory recovery 
percentage results for the assay of AZL and/with CLT in 
their laboratory prepared mixtures indicate the accuracy of 
the method (Table 2). Repeatability (intra-day) and inter-
mediate precision (inter-day) were assessed using three 
concentrations and three replicates of each concentration. 
The relative standard deviations were found to be very small 
indicating reasonable repeatability and intermediate preci-
sion of the proposed method (Table 3).
3.3.4. Specificity. The specificity of the method was inves-
tigated by observing any interference encountered from com-
mon tablet excipients, and it was confirmed that the signals 
 measured was caused only by the analytes. The inactive ingre-
dients in Edarbyclor® are mannitol, microcrystalline cellu-
lose, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, 
crospovidone, magnesium stearate, hypromellose 2910, talc, 
 titanium dioxide, ferric oxide red, polyethylene glycol 8000, and 
printing ink gray F1. It was found that the excipients did not 
interfere with the results (Table 2). For the spectrophotometric 
method, it was found that AZL and CLT can be determined 
Ebeid et al
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Figure 9. Synchronous fluorescence spectra for 0.06 µg ml-1 of (a) AZL and (b) CLT upon excitation at 260 nm against (c) methanol blank using the 
described parameters.
simultaneously either in their laboratory prepared mixtures or 
in their co- formulated tablets (Table 2). On the other hand, the 
spectrofluorimetric method was only able to determine AZL 
in presence of CLT in methanol (Table 2).
3.3.5. Stability. Stabilities of the standard stock solutions 
of AZL and CLT, stored at 2–8°C, were evaluated at vari-
ous time points for more than one month. The concentrations 
of freshly prepared solutions and those aged for one month 
were calculated by the methods developed, and the  difference 
between them was found to be less than 2%. Also, the pre-
pared solutions for analysis were found to be stable for at 
least three days at 2–8°C and for a day at room temperature. 
These solutions can therefore be used during this interval of 
time without the results being affected.
4. Conclusion
Rapid, sensitive, inexpensive, and simple spectrophotomet-
ric and spectrofluorimetric methods were developed and 
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Table 3. Intra- and inter-day validation for the spectroscopic methods.
TECHNIQUE MEDICATION CONCENTRATION  
(µg mL-1)
INTRA-DAY ASSAY  
FOUND ± % R.S.Da
INTER-DAY ASSAY 
FOUND ± %R.S.Da
spectrophotometric
AZl
12.000 12.619 ± 0.63 12.124 ± 1.68
20.000 20.124 ± 2.02 20.258 ± 1.01
30.000 29.813 ± 1.23 29.457 ± 1.19
clt
4.000 4.028 ± 0.32 4.051 ± 0.64
8.000 7.905 ± 1.63 8.054 ± 1.66
12.000 11.923 ± 1.08 11.789 ± 1.58
Spectrofluorimetric AZl
0.015 0.015 ± 2.09 0.015 ± 2.92
0.030 0.030 ± 2.22 0.030 ± 2.77
0.050 0.050 ± 1.36 0.050 ± 2.88
aMean and % R.S.D. of three determinations.
Table 2. Assay results for the determination of the studied drugs in their laboratory prepared mixtures and dosage form.
TECHNIQUE COMPOUND SYNTHETIC MIXTURES (CLT:AZL) (1.0:1.6) DOSAGE FORM (EDARBCYCLOR® TABLETS)
AMOUNT TAKEN
(µg mL-1)
AMOUNT FOUND
(µg mL-1)
% FOUND AMOUNT TAKEN
(µg mL-1)
AMOUNT FOUND
(µg µL-1)
% FOUND
spectrophotometric
clt
6.000 6.045 100.74 6.000 6.045 100.74
10.000 9.839 98.39 10.000 10.286 102.86
18.000 17.875 99.31 18.000 17.652 98.07
Mean recovery% 99.48 100.56
± %R.S.D 1.19 2.39
AZl
9.600 9.813 102.22 9.600 9.813 102.22
16.000 15.813 98.83 16.000 16.480 103.00
28.800 28.480 98.89 28.800 28.480 98.89
Mean recovery% 99.98 101.37
± %R.S.D 1.94 2.15
Spectrofluorimetric
AZl
0.0384 0.039 101.26 0.0384 0.037 97.40
0.0576 0.058 100.12 0.0576 0.057 99.30
0.0768 0.077 100.47 0.0768 0.076 98.80
Mean recovery% 100.62 98.50
± %R.S.D 0.58 1.00
Each result is the average of three separate determinations.
 validated for determination of AZL in its combination with 
CLT either in their laboratory prepared mixtures or in their 
combined pharmaceutical formulation. The proposed meth-
ods have many advantages regarding analysis time, sensitiv-
ity, and cost. Finally, the proposed methods can be used for 
the quality control of the cited drugs in ordinary laboratories 
without pre-separation.
Abbreviations
AZL, azilsartan medoxomil; CLT, chlorthalidone; PBS, 
phosphate buffer solution; RIF, relative fluorescence intensity.
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